Ken Griffin Intellia Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$19.72 - $27.36 $114,376 - $158,688	-5,800 Reduced 4.51%	122,900 $2.53 Million
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $520,520 - $707,720	26,000 Added 25.32%	128,700 $2.88 Million
Q1 2024 May 15, 2024	SELL	$23.82 - $32.8 $1.67 Million - $2.3 Million	-70,000 Reduced 40.53%	102,700 $2.83 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $1.53 Million - $2.14 Million	66,100 Added 62.01%	172,700 $5.27 Million
Q3 2023 Nov 14, 2023	SELL	$31.62 - $45.78 $1.22 Million - $1.77 Million	-38,700 Reduced 26.63%	106,600 $3.37 Million
Q2 2023 Aug 14, 2023	BUY	$34.58 - $46.03 $3.18 Million - $4.23 Million	92,000 Added 172.61%	145,300 $5.93 Million
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $136,530 - $183,762	-4,100 Reduced 7.14%	53,300 $1.99 Million
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $1.22 Million - $2.29 Million	-36,600 Reduced 38.94%	57,400 $2 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $1.01 Million - $1.35 Million	18,800 Added 25.0%	94,000 $5.26 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $916M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.